Melanotan sustained release products

Melanotan sustained release products

Australian EpiTan company has applied for new international patents for all the sustained-release dosage forms of its leading product Melanotan after the early clinical results were confirmed. The company said that they continued their daily bolus study of melanin-stimulating products, but this time found that higher dosages were needed. The patent application covers a variety of existing sustained-release dosage forms, including subcutaneous implants, topical formulations, oral formulations, and other dosage forms. The company has completed a phase II clinical trial of the drug to reduce sunburn, and looks forward to applying for the prevention and treatment of skin damage caused by ultraviolet rays.